Memantine and Validation of a New Alzheimer's Disease Scale

Open Label, Single-Arm, Multi-Centre, Study to Validate a New Alzheimer's Disease Scale in Patients With DAT, Treated With Memantine

To validate a new Alzheimer's Disease scale against other rating tools in subjects with dementia of Alzheimer's type, treated with memantine.

Inclusion Criteria:

• Diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of Alzheimer's type.
• Signed informed consent prior to the initiation of any study specific procedures.
• Sight and hearing (a hearing aid is permitted) are sufficiently good to allow the undertaking of study-related procedures and psychometric tests.

Exclusion Criteria:

• Evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease.
• Intake of any medication that is contra-indicated in combination with memantine.
• History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to ingredients of memantine or lactose.
• Known or suspected history of alcoholism or drug abuse within the past 2 years.
• Current or previous treatment with memantine or participation in an investigational study with memantine.